SS-31 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What SS-31 Does & How It Works

What It Does, Functional Outcomes

• Improves ATP production efficiency in mitochondria damaged by disease, aging, or ischemic injury
• Increases muscle strength and exercise capacity in populations with mitochondrial dysfunction
• Protects heart and kidney cells from ischemic injury by maintaining mitochondrial energy output during blood flow interruption
• Reduces mitochondria-driven inflammation by stabilizing the structural components that, when damaged, trigger inflammatory cascades
• Reverses measurable markers of cardiac aging, including mitochondrial inefficiency and cardiac fibrosis
• Promotes removal of damaged mitochondria and formation of healthier, more interconnected mitochondrial networks
• Protects against programmed cell death (apoptosis) triggered by mitochondrial failure

How It Works, Mechanism of Action

Cardiolipin Binding and Respiratory Supercomplex Stabilization (Evidence: Human and Animal)

Cardiolipin is a phospholipid found exclusively in the inner mitochondrial membrane. It is the structural anchor for the protein complexes that generate ATP. Damage it, and the entire energy-producing apparatus loses its geometry and efficiency. SS-31 binds directly to cardiolipin through electrostatic interactions between its positively charged residues and cardiolipin's negative charge. This stabilizes the membrane domains where respiratory chain supercomplexes assemble.

This binding also protects the Met80-Fe bond between cardiolipin and cytochrome c. That bond, when broken by oxidative stress, converts cytochrome c from an electron carrier into a peroxidase (an enzyme that drives destructive lipid breakdown) that triggers damaging chain reactions throughout the membrane.

ATP Synthasome Stabilization and Protein-Level Interactions (Evidence: Human and Animal)

Beyond the membrane itself, SS-31 interacts directly with protein complexes at the inner mitochondrial membrane. Proteomic analysis using chemical cross-linking with mass spectrometry identified 12 key protein interactors. These include components of the ATP synthasome, which is the supercomplex comprising ATP synthase, the adenine nucleotide translocator (ANT), and creatine kinase. That supercomplex is responsible for producing and transporting ATP.

These interactions improve the efficiency of oxidative phosphorylation (the process that converts the electrochemical gradient across the inner membrane into usable ATP). They have also been shown to increase ADP uptake capacity in aged skeletal muscle specifically.

Targeted ROS Scavenging and Antioxidant Enzyme Upregulation (Evidence: Animal and In vitro)

SS-31's dimethyltyrosine (Dmt) residue provides intrinsic antioxidant capacity. At the inner mitochondrial membrane, which is the primary site of reactive oxygen species (ROS) generation within the electron transport chain, SS-31 directly neutralizes hydrogen peroxide, hydroxyl radicals, and peroxynitrite. Critically, this scavenging happens at the source rather than systemically.

SS-31 also upregulates the expression of SOD1, SOD2, and catalase, which are the body's own antioxidant enzyme systems. This amplifies the protective effect beyond direct chemical neutralization.

Mitochondrial Dynamics Modulation and Anti-Apoptotic Signaling (Evidence: Animal and In vitro)

SS-31 influences both the physical structure of mitochondria and the signals that determine whether a cell lives or dies. On the dynamics side, it promotes the formation of larger, more interconnected mitochondrial networks. It also enhances the selective removal of damaged mitochondria (mitophagy) and reduces the excessive fragmentation that occurs under stress.

On the apoptosis side, it inhibits the release of cytochrome c into the cytoplasm. It also reduces the recruitment of the pro-death protein BAX to the mitochondrial membrane. Additionally, it prevents opening of the mitochondrial permeability transition pore (mPTP), which is a critical event in traumatic brain injury and cardiac ischemia, while increasing expression of the anti-apoptotic protein Bcl-2.

Redox Homeostasis Restoration via S-Glutathionylation Reversal (Evidence: Animal)

With aging and chronic oxidative stress, a chemical modification called S-glutathionylation (the attachment of glutathione molecules to cysteine residues on proteins in ways that alter their shape and impair their function) accumulates on mitochondrial proteins. SS-31 reverses this modification. It restores the function of mitochondrial proteins that had been progressively impaired by this age-related change.

SS-31 Molecular Profile

Structure reference: View on PubChem (CID 11764719), Publishing team: retrieve 2D structure image from this link.

SS-31 Uses & Benefits

Barth Syndrome and Genetic Mitochondrial Disease

Barth syndrome is a rare X-linked disorder caused by mutations in the TAZ gene, which encodes tafazzin (an enzyme responsible for remodeling cardiolipin). When tafazzin is deficient, cardiolipin structure is defective. The result is severe mitochondrial dysfunction driving dilated cardiomyopathy, skeletal muscle weakness, and growth failure. SS-31's primary mechanism - direct cardiolipin binding and stabilization - addresses the root molecular defect in Barth syndrome rather than managing symptoms downstream of it.

The TAZPOWER Phase 2/3 trial demonstrated 45% improvement in knee extensor strength and 40% enhancement in cardiac stroke volume over 48 weeks. This led to FDA accelerated approval of Forzinity in September 2025 as the first approved treatment for this condition. (Evidence: Strong, Reid Thompson et al., Genetics in Medicine, 2021)

Cardiac Aging and Heart Failure

Mitochondrial dysfunction is a central driver of age-related cardiac decline. The aging heart accumulates cardiolipin oxidation, respiratory supercomplex disassembly, and increased proton leak (a measure of how much energy the mitochondria waste as heat rather than converting to ATP). All of these reduce the efficiency of ATP production in a tissue with among the highest energy demands in the body.

SS-31 has been studied in aged animal models, explanted failing human heart tissue, and clinical heart failure trials. An 8-week aged mouse cardiac study demonstrated reversal of multiple aging markers without increasing the number of respiratory chain complex proteins. This means SS-31 improved the efficiency of existing mitochondrial machinery rather than simply building more of it. (Evidence: Moderate, Chiao et al., eLife, 2020; Chatfield et al., JACC: Basic to Translational Science, 2019)

Primary Mitochondrial Myopathy

Primary mitochondrial myopathy (PMM) is a group of inherited disorders where genetic defects in the mitochondrial or nuclear DNA impair the respiratory chain. The result is muscle weakness, exercise intolerance, and fatigue. SS-31 was evaluated in a Phase 2 dose-escalation trial across multiple PMM subtypes. The trial documented dose-dependent increases in muscle ATP production and improvements in mitochondrial respiratory chain function. Exercise tolerance improved in some patient subgroups.

Primary endpoints were not consistently met across all subtypes, reflecting the significant heterogeneity within the PMM category. (Evidence: Moderate, Karaa et al., Neurology, 2018)

Renal Protection and Kidney Ischemia

The kidney's tubular cells are among the most mitochondria-dense in the body and are acutely vulnerable to ischemic injury. When blood flow to the kidney is interrupted, the rapid loss of ATP triggers apoptotic cell death in tubular tissue. SS-31 has been studied in renal ischemia models and a Phase 2a clinical trial in renal artery stenosis patients.

The foundational mechanistic evidence established that SS-31 re-energizes mitochondria in ischemic kidney tissue by restoring cardiolipin function during the ischemic period. Diabetic nephropathy models have additionally demonstrated inhibition of mitochondrial fission and protection of tubular cell integrity. (Evidence: Moderate, animal models and limited human data)

Aging Biology and Geroscience Applications

Aging mitochondria show a characteristic pattern of dysfunction: cristae (the internal folds of the inner mitochondrial membrane) disruption, cardiolipin oxidation, respiratory supercomplex disassembly, accumulation of S-glutathionylation on functional proteins, and progressive decline in bioenergetic output. These are all processes that SS-31's mechanism directly targets.

The compound has emerged as a significant research tool in geroscience for this reason. Published studies demonstrate reversal of age-related redox stress, improvement in ADP uptake capacity in aged skeletal muscle, and reversal of cardiac aging markers within 8-week treatment windows in animal models. (Evidence: Moderate for aging biology, Campbell et al., Free Radical Biology and Medicine, 2019; Stuppard et al., GeroScience, 2023)

Skeletal Muscle Function and Exercise Capacity

Beyond disease contexts, SS-31 has demonstrated relevance to the age-related decline in skeletal muscle energy production that underlies exercise intolerance and sarcopenia. Stuppard et al. identified that SS-31 improves ADP uptake via the adenine nucleotide translocator (ANT) in aged skeletal muscle. ANT is the protein that exchanges ADP for ATP across the inner mitochondrial membrane, functioning essentially as the loading dock of the mitochondrial power plant.

Improving this loading dock function directly translates to increased respiratory capacity during exercise. This finding provides a mechanistic explanation for the exercise capacity improvements observed in clinical trial populations. (Evidence: Moderate, Stuppard et al., GeroScience, 2023)

Where This Guide Comes From

SS-31 Results & Timelines

SS-31's timeline profile is shaped by an unusual pharmacological feature: its plasma half-life is roughly 2-4 hours, yet the improvements it produces in mitochondrial function persist for days to weeks. This means that early in a protocol, the subjective experience may lag behind what is happening at the mitochondrial level. What users and researchers observe tends to track the timeline of functional improvement rather than the compound's plasma presence.

Energy, Fatigue, and General Function

• Week 1-3: Initial reports are often subtle. Some users in investigational contexts describe modest reductions in fatigue and slightly improved exercise recovery, though effects at this stage are not consistently documented across sources.
• Week 4-8: More consistent energy improvements and reduced post-exertion fatigue are commonly noted in practitioner-tracked protocols. The 8-week aged mouse cardiac study documented measurable marker reversal within this window.
• Month 2-4: Functional improvements in exercise capacity become more pronounced in those tracking output. This aligns with the timeframe in which clinical trial populations showed meaningful strength gains.

Muscle Strength and Exercise Capacity

• Month 1-2: Early strength signal may be present but is typically modest. Variability is high at this stage based on underlying condition.
• Month 2-4: The primary clinical evidence for meaningful strength improvements comes from the TAZPOWER 48-week endpoint, but improvement trajectories in that trial suggest meaningful gains were accumulating through this window.
• Week 48 and beyond: The 48-week TAZPOWER data showed 45% muscle strength improvement. The open-label extension indicates continued benefit with sustained use.

Cardiac and Hemodynamic Function

• Acute: IV infusion studies in ischemia contexts suggest protective effects operate within hours in acute clinical scenarios.
• Week 8: Reversal of cardiac aging markers documented in the aged mouse 8-week study.
• Month 3-12: Cardiac stroke volume improvements in the TAZPOWER trial were documented through the 48-week endpoint. The trajectory over months 3-12 in the clinical data supports progressive rather than abrupt improvement.

How to Administer SS-31

Subcutaneous Injection (SubQ)

Subcutaneous injection is the primary route used in the chronic clinical trial programs for SS-31, including the TAZPOWER Barth syndrome trials and the primary mitochondrial myopathy dose-escalation study. SS-31's high water solubility, a deliberate design feature of the compound, facilitates clean dissolution and consistent SubQ delivery. The most commonly reported adverse events across clinical trials (mild injection site reactions) are directly associated with this route and are generally transient.

Intramuscular Injection (IM)

Intramuscular injection is not the documented primary route for SS-31 in clinical trial protocols. The SubQ route has been used consistently in the published human trial data. IM administration has not been specifically evaluated in published research for this compound.

Oral

Oral administration is not documented as viable for SS-31. As a peptide, SS-31 is susceptible to proteolytic degradation (breakdown by digestive enzymes) in the gastrointestinal environment. Its mechanism requires systemic delivery for cellular uptake and mitochondrial targeting. While the D-Arginine modification at position 1 provides resistance to some peptidases, the gastric acid and intestinal protease environment would be expected to degrade the compound before meaningful absorption occurs. No oral formulation or oral bioavailability data for SS-31 has been published.

Intravenous Infusion (IV)

IV infusion has been used in acute and perioperative cardiac research contexts, including the chronic heart failure canine model at 0.05 mg/kg per hour as a continuous infusion. In acute ischemia-reperfusion studies, IV delivery provides rapid systemic distribution appropriate for time-sensitive protective scenarios. IV administration in investigational human contexts would require clinical oversight appropriate to that route.

SS-31 Dosage & Cycle Length

SS-31 sits in an unusual position for a peptide guide. It has more clinical trial data behind it than almost any compound in this library, spanning over 50 studies across two decades. Yet specific dose numbers from the pivotal human trials are not fully disclosed in the published literature. What exists is a framework: the routes and durations used, the dose-response patterns observed, and the pharmacokinetic logic that informs how the SS-31 peptide is typically approached in investigational contexts.

Overall dosing range (clinical research reference figures): The Karaa et al. Phase 2 dose-escalation trial (Neurology, 2018) tested ascending subcutaneous dose tiers in primary mitochondrial myopathy patients and documented dose-dependent increases in muscle ATP production at higher dose levels. The exact milligram amounts were not fully specified in the published paper, but the trial design used multiple discrete dose levels with a cautious upward titration approach. The TAZPOWER Barth syndrome program used daily subcutaneous injection across a 48-week primary endpoint and over 8 years of open-label extension. These are clinical trial reference points, not generalized dosing figures for investigational use.

How the goal shifts where you land:

• Lower dose tiers: Used in the dose-escalation PMM research context; characterized by cautious titration to assess tolerability before advancing
• Higher dose tiers: Associated with more robust improvements in ATP production and muscle function in the PMM trials; dose-dependent increases in muscle ATP production were documented (Karaa et al., Neurology, 2018)
• Acute and perioperative contexts: IV infusion dosing (0.05 mg/kg per hour) was used in the chronic heart failure canine model, a different paradigm from chronic SubQ protocols and not directly applicable to standard investigational use

Frequency: Daily subcutaneous injection in the chronic-use clinical trials (TAZPOWER Barth syndrome program, primary mitochondrial myopathy studies)

Cycle length: The TAZPOWER trial ran 48 weeks as the primary endpoint with an open-label extension that has generated over 8 years of continuous use data. The cardiac aging mouse study used 8 weeks and demonstrated measurable marker reversal within that window. Investigational use in the research community tends to follow shorter cycles than the clinical trial programs, though no standardized investigational cycle length has been established.

A note on the pharmacodynamic and pharmacokinetic dissociation: SS-31's plasma half-life is approximately 2-4 hours, yet improvements in mitochondrial function persist for days to weeks after dosing. This documented phenomenon suggests that dosing frequency requirements may be lower than the half-life alone would imply. The exact practical implication for investigational protocols has not been formally characterized. Daily dosing is what the clinical trials used; whether less frequent dosing would be equally effective in investigational contexts remains an open question.

The FDA-approved Forzinity formulation: Dosing for Barth syndrome under the approved Forzinity label is determined by the prescribing physician per the FDA-approved prescribing information. This is a prescription medication for a specific patient population (individuals weighing at least 30 kg with confirmed Barth syndrome) and operates entirely outside the research compound context.

SS-31 Vial Sizes, Costs & Quality

Common vial sizes: 5 mg and 10 mg are the most commonly available sizes for SS-31 as a research compound; some suppliers offer 2 mg vials

Typical cost range: $80-$180 per vial for U.S.-manufactured research-grade SS-31 at current market pricing. SS-31's more complex synthesis (four amino acids including the non-natural Dmt residue) places it in the higher-cost tier among research peptides, and the pricing reflects that synthesis complexity.

Storage, lyophilized (dry powder):

• Temperature: -20 degrees C for long-term storage; stable at -20 degrees C for extended periods
• Shelf life: Typically 2 or more years when stored correctly in lyophilized form
• Light sensitivity: Protect from light; store in original sealed container

Storage, reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C after reconstitution
• Use window: Typically 7-14 days once reconstituted; use within this window for optimal stability

Normal appearance after reconstitution: SS-31 dissolves into a clear, colorless solution. Its high water solubility, one of the deliberately engineered properties of the compound, means it should dissolve cleanly and completely without cloudiness or visible particulates.

Signs of degradation: Heavy cloudiness beyond what occurs during normal dissolution, visible particulates remaining in solution, discoloration (yellow or amber tinge in solution that was previously clear), or unusual odor are indicators of potential degradation. Degraded SS-31 should not be used.

Quality Considerations

SS-31 contains two non-standard residues: D-Arginine (the mirror-image form of the natural amino acid) and the non-natural dimethyltyrosine (Dmt). Both require specialized synthesis steps that many standard peptide manufacturers are not equipped to execute cleanly. When synthesis costs get cut, purity at one of these non-standard residue steps is almost always where the shortfall shows up. An impure batch may contain active Dmt degradation products or racemized D-Arg (a form of D-Arginine that has flipped back toward its inactive mirror image), and either contaminant behaves differently from the intended compound. The only meaningful way to verify what is actually in a vial is a certificate of analysis from independent third-party HPLC testing. If a supplier does not provide one, that tells you something important. U.S.-manufactured SS-31 from established research peptide suppliers comes with documented synthesis standards, third-party testing, and full chain of custody from synthesis to shipment, which is a meaningful distinction from overseas alternatives operating without those controls.

SS-31 Side Effects & Safety

SS-31 has one of the more substantial safety databases of any research peptide, accumulated across more than 50 clinical trials and an open-label extension program that has run over 8 years in Barth syndrome patients. That breadth of data provides meaningful context for the safety picture.

Side Effect Spectrum

Contraindications

• Known hypersensitivity to SS-31 (elamipretide) or any component of the formulation: Standard contraindication for any peptide compound; anaphylactic reaction, while not prominently reported, cannot be excluded
• Active malignancy: Insufficient data to confirm safety; SS-31's effects on mitochondrial bioenergetics in cancer cells, where altered mitochondrial metabolism is a characteristic feature, have not been formally studied in humans with active cancer
• Pediatric use below established weight thresholds: The FDA-approved Forzinity label specifies eligibility for patients weighing at least 30 kg; use outside this weight range in pediatric populations has not been studied in the approved indication context

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Use of the research compound form (outside the FDA-approved Forzinity indication) in pediatric populations is not appropriate without medical supervision
• Individuals with mitochondrial diseases not yet formally studied: SS-31's effects have been characterized in specific mitochondrial disease contexts (Barth syndrome, PMM subtypes); individuals with other mitochondrial disorders should be aware that the response profile for their specific genetic defect may differ from studied populations
• Renal or hepatic impairment: Formal pharmacokinetic studies in these populations have not been published in available summaries; appropriate caution is warranted

Red Flags, Stop Use and Seek Medical Attention If:

• Signs of a systemic allergic reaction: widespread hives, difficulty breathing, throat tightening, or rapid swelling of the face or mouth
• Severe or worsening injection site reaction beyond expected mild local effects: spreading redness, warmth, significant swelling, or discharge suggesting infection
• Unexpected cardiac symptoms: chest pain, significant palpitations, or shortness of breath not attributable to the underlying condition being addressed
• Significant nausea, vomiting, or systemic symptoms suggesting an adverse reaction rather than the normal tolerability profile

Drug and Compound Interactions

No specific drug-drug interactions have been formally characterized in the published literature for SS-31. Given its mechanism of action, which is concentrated at the inner mitochondrial membrane with direct effects on bioenergetics, theoretical interactions with other mitochondria-active compounds (CoQ10, NAD+ precursors, other mitochondria-targeting agents) are plausible but have not been studied. Compounds that alter mitochondrial membrane potential may theoretically influence SS-31's cellular distribution, though its uptake is documented as membrane-potential-independent, which may limit this interaction vector. Researchers and clinicians should exercise caution with concurrent use of compounds that have not been co-studied with SS-31.

SS-31 Research & Studies

SS-31's research base is genuinely unusual among compounds discussed in the peptide and biohacking communities. It has been studied in more clinical trials than most FDA-approved drugs, not as a supplement or research curiosity, but in properly designed and published investigations across multiple disease states. Understanding what that evidence actually shows, and where its limits are, is what this section is about.

Pharmacokinetics & Metabolism

Absorption & Bioavailability

SS-31 is highly water-soluble, which facilitates consistent absorption via subcutaneous injection, the primary route used in chronic clinical trial protocols. Bioavailability from SubQ injection has not been formally published as a percentage in the available literature. The compound's plasma pharmacokinetics have been characterized across human studies, and the absorption profile supports once-daily dosing as used in the pivotal trials.

Distribution

SS-31 concentrates at the inner mitochondrial membrane at approximately 5,000-fold higher levels than in the surrounding cytoplasm. It distributes to mitochondria-rich tissues: heart, kidney, skeletal muscle, and brain. These correspond to its documented areas of pharmacological effect. It does not enter the mitochondrial matrix; it accumulates at the membrane surface. Whether it crosses the blood-brain barrier in humans has not been definitively characterized in published pharmacokinetic data, though its neuroprotective effects in preclinical models suggest some CNS penetration.

Half-Life

Plasma half-life in humans is approximately 2-4 hours, placing it firmly in the short-acting category for injectable peptides. This is well-established across human pharmacokinetic data.

Metabolism & Elimination

The D-Arginine at position 1 of the SS-31 sequence confers resistance to peptidase degradation (enzymatic breakdown), a deliberate design feature that extends in vivo stability compared to all-L-amino acid peptides of similar length. Elimination is expected to proceed via proteolytic degradation of the remaining L-amino acid residues and renal excretion of breakdown products, though detailed elimination pathway data is not available in published summaries.

The dissociation between SS-31's 2-4 hour plasma half-life and its days-to-weeks pharmacodynamic duration is one of the most scientifically interesting features of this SS-31 peptide and remains incompletely explained. Proposed mechanisms include tissue retention beyond plasma clearance, downstream signaling cascades that continue after drug clearance, structural mitochondrial remodeling that becomes self-sustaining, and possible transcriptional or epigenetic changes. None of these explanations has been definitively confirmed.

Mechanistic Research

Cardiolipin Binding and Respiratory Supercomplex Stabilization (Evidence: Human and Animal, Chavez et al., PNAS, 2020)

Using chemical cross-linking with mass spectrometry (XL-MS), Chavez et al. identified SS-31's binding interactions at the inner mitochondrial membrane with molecular precision. The analysis confirmed that SS-31 binds to cardiolipin-enriched membrane domains where respiratory chain supercomplexes assemble. It also identified 12 key protein interactors including components of the ATP synthasome, which is the supercomplex responsible for both producing and transporting ATP.

The study revealed that SS-31's effects on bioenergetics operate through both lipid (cardiolipin) and protein (ATP synthasome components) interactions simultaneously. This explains the breadth of its downstream functional effects.

S-Glutathionylation Reversal and Aging Biology (Evidence: Animal, Campbell et al., Free Radical Biology and Medicine, 2019)

S-glutathionylation is a post-translational modification (a chemical change to a protein that occurs after it has been built, altering its shape and function). This modification is essentially an oxidative chemical addition to cysteine residues on proteins. It accumulates with aging and oxidative stress and impairs enzymatic activity across multiple mitochondrial proteins. Campbell et al. demonstrated that SS-31 reverses this modification, restoring function to proteins that had been impaired by this age-related change. This finding connects SS-31's mechanism directly to a well-characterized molecular hallmark of biological aging, rather than just a disease-state pathology.

ANT/ADP Uptake and Respiratory Capacity in Aged Skeletal Muscle (Evidence: Human tissue and Animal, Stuppard et al., GeroScience, 2023)

Stuppard et al. demonstrated that SS-31 improves ADP uptake via the adenine nucleotide translocator (ANT) in aged skeletal muscle, increasing respiratory capacity. ANT is the protein responsible for exchanging ADP for ATP across the inner mitochondrial membrane: importing the substrate that drives ATP synthesis and exporting the finished product. Impaired ANT function in aged muscle is a direct contributor to the bioenergetic deficit underlying age-related exercise intolerance and sarcopenia. This study provided a specific mechanistic explanation for how SS-31 improves exercise capacity in aging populations.

Condition-Focused Research

Barth Syndrome and Genetic Mitochondrial Disease {#research-barth}

The TAZPOWER Phase 2/3 trial was a randomized, double-blind, placebo-controlled study of elamipretide in Barth syndrome patients, followed by an open-label extension. The primary endpoint was skeletal muscle function, measured by knee extensor strength. Results at 48 weeks showed a 45% improvement in knee extensor strength and a 40% enhancement in cardiac stroke volume in treated patients versus placebo.

The trial's open-label extension has now generated over 8 years of continuous safety and efficacy data. This is one of the longest datasets for any experimental mitochondria-targeted therapeutic and formed a foundation for the FDA's accelerated approval decision in September 2025. (Evidence: Strong, Reid Thompson et al., Genetics in Medicine, 2021)

Cardiac Aging in an Alzheimer's Disease Mouse Model {#research-cardiac}

Chiao et al. used an 8-week SS-31 treatment course in an aged Alzheimer's disease mouse model to evaluate effects on cardiac aging markers. The results showed reversal of multiple established aging markers: reduced proton leak (a measure of mitochondrial inefficiency), increased membrane potential, reduced ROS generation, and reduced cardiac fibrosis. Notably, the improvements occurred without changes in the levels of respiratory chain complex proteins. This means SS-31 improved the efficiency of existing mitochondrial machinery rather than simply building more of it.

Chatfield et al. demonstrated in parallel that elamipretide improves mitochondrial function in explanted failing human heart tissue, establishing direct relevance to human heart failure pathology beyond animal models. (Evidence: Moderate, Chiao et al., eLife, 2020; Chatfield et al., JACC: Basic to Translational Science, 2019)

Renal Ischemia and Kidney Protection {#research-renal}

Birk et al. established the foundational renal evidence for SS-31, demonstrating that the compound re-energizes mitochondria in ischemic kidney tissue by restoring cardiolipin function. The kidney is particularly vulnerable to ischemia because its tubular cells are among the most mitochondria-dense in the body. The loss of ATP during ischemia rapidly triggers apoptotic cell death. SS-31's ability to protect cardiolipin and maintain ATP production during the ischemic period, and to limit reperfusion injury when blood flow resumes, provides mechanistic protection that no general antioxidant approach can match. A Phase 2a clinical trial in renal artery stenosis patients extended these findings toward human application. (Evidence: Moderate, animal models and limited human data)

Primary Mitochondrial Myopathy {#research-pmm}

The Phase 2 dose-escalation trial by Karaa et al. evaluated elamipretide across multiple doses in primary mitochondrial myopathy patients with respiratory chain complex deficiencies. The trial documented improvements in mitochondrial respiratory chain function and dose-dependent increases in muscle ATP production. Exercise tolerance improved in some patient subgroups.

However, primary endpoints were not consistently met across all mitochondrial myopathy subtypes. This reflects the significant heterogeneity of this disease category: patients with different underlying genetic defects respond differently to the same intervention. (Evidence: Moderate, Karaa et al., Neurology, 2018)

Safety & Tolerability Research

Across more than 50 clinical trials spanning two decades, SS-31 has accumulated one of the more substantial safety records of any research peptide. The most consistently documented adverse event is mild injection site reactions: redness, swelling, and discomfort at the injection site occurring with subcutaneous administration. Nausea was reported in some trials at generally mild severity. Serious drug-related adverse events have not been consistently documented in the published trial summaries available.

The TAZPOWER open-label extension, now exceeding 8 years of continuous daily use in Barth syndrome patients, represents the longest available safety dataset for this compound and has not surfaced a pattern of serious cumulative toxicity. The selective action of SS-31 on dysfunctional mitochondria, with minimal apparent effect on normal, healthy mitochondria, is the likely mechanistic basis for its favorable therapeutic window.

Research Limitations

Despite its extensive clinical trial history, SS-31's research base has meaningful gaps. Specific dose amounts from the pivotal human trials, including the TAZPOWER primary dose and the exact dose ranges from the primary mitochondrial myopathy program, have not been published in sufficient detail for generalized dosing guidance. The most robust human evidence is concentrated in rare disease populations (Barth syndrome) where a specific genetic defect directly matches SS-31's mechanism.

Whether the compound produces meaningful functional improvements in the broader aging and general health optimization context, where mitochondrial dysfunction is present but not genetically defined, has not been formally characterized in controlled human studies. Pharmacokinetic data in renally or hepatically impaired populations is not available in published summaries. Human neurological trial data remains preclinical. The mechanism behind SS-31's prolonged pharmacodynamic duration relative to its short plasma half-life remains incompletely explained.

Is SS-31 Legal? Regulatory & Sports Status

FDA status: SS-31 (elamipretide) received FDA accelerated approval on September 19, 2025, under the brand name Forzinity, for the treatment of Barth syndrome in patients weighing at least 30 kg. This is the first FDA-approved treatment for Barth syndrome and the first FDA-approved mitochondria-targeted therapeutic. Continued approval under the accelerated pathway is contingent on confirmatory trials demonstrating direct clinical benefit. Outside the Barth syndrome indication, SS-31 remains a research compound without FDA approval for human use.

Research Use Only (RUO): In virtually all contexts outside of the FDA-approved Forzinity indication for Barth syndrome, SS-31 is classified as a research compound not approved for human use. Researchers, clinicians, and investigational users operate under this classification in their respective jurisdictions.

WADA / USADA status: SS-31 (elamipretide) does not currently appear on the WADA prohibited list as a specifically named compound. However, WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and the catchall prohibition on other anabolic agents could apply depending on classification. Athletes subject to anti-doping rules should consult their national anti-doping organization for current guidance, as WADA classifications are updated annually and the landscape for novel mitochondria-targeted compounds is evolving.

Country-specific notes: The FDA accelerated approval in September 2025 makes Forzinity available as a prescription medication in the United States for the approved Barth syndrome indication. Regulatory status in other markets (EU, UK, Canada, Australia) has not been confirmed in available sources as of July 2026. Researchers and practitioners in those jurisdictions should verify current classification with their relevant regulatory authority. Regulatory designations received by elamipretide during development include Orphan Drug, Fast Track, Priority Review, and Rare Pediatric Disease designations, all in the United States.

Detection: No standard anti-doping detection methodology for SS-31 has been published in the available literature. As a tetrapeptide with a short plasma half-life and selective tissue distribution, standard detection windows would be expected to be limited. In the absence of published detection data, estimated windows should be treated as unknown.

SS-31 vs. Alternatives

Commonly Paired With, Synergistic Stacks

• SS-31 + NAD+ precursors (NMN or NR): This pairing targets mitochondrial health from complementary angles. SS-31 stabilizes the structural membrane components and protein complexes that enable ATP synthesis, while NAD+ precursors replenish the nicotinamide that drives the electron transport chain upstream. The combination addresses both the structural dysfunction (SS-31's domain) and the substrate limitation (NAD+ precursors' domain) that contribute to age-related bioenergetic decline. This stack appears frequently in geroscience research discussions and longevity practitioner protocols.
• SS-31 + CoQ10: CoQ10 is a fat-soluble antioxidant and electron carrier within the electron transport chain. Unlike SS-31's membrane-localized, targeted mechanism, CoQ10 functions as a mobile electron shuttle between respiratory chain complexes. Some practitioners combine them on the basis that CoQ10 addresses the carrier function while SS-31 addresses the membrane architecture that makes CoQ10's work possible. This combination has not been studied head-to-head in published research.
• SS-31 + BPC-157: This combination appears in practitioner and community contexts oriented toward injury recovery and tissue protection, pairing SS-31's mitochondrial cytoprotection with BPC-157's growth factor and angiogenic activity. The rationale is complementary cellular protection during recovery: SS-31 at the energy production level, BPC-157 at the tissue repair level. No published combination data exists.

Alternatives, When Another Compound May Be Considered

CoQ10 (Ubiquinol/Ubiquinone) CoQ10 is the most widely used mitochondria-supporting supplement and the compound most commonly evaluated as a comparator to SS-31. It functions as an electron carrier and antioxidant within the electron transport chain. For individuals seeking general mitochondrial support with a long safety track record, widely available oral formulations, and established evidence in cardiovascular health and statin-associated myopathy, CoQ10 is the practical starting point. A 2024 review published in Mitochondrion specifically examined SS-31's advantages over natural antioxidants including CoQ10 in suppressing inflammation, maintaining mitochondrial dynamics, and preventing apoptosis.

MitoQ (Mitoquinone) MitoQ is a mitochondria-targeted antioxidant created by conjugating CoQ10 to a triphenylphosphonium (TPP) cation, which drives accumulation in mitochondria via the membrane potential gradient. Unlike the SS-31 peptide, MitoQ's uptake depends on an intact membrane potential, meaning it may be less effective in severely dysfunctional mitochondria where that potential is diminished. MitoQ is available as an oral supplement with a degree of clinical evidence in cardiovascular and aging contexts, making it more accessible than injectable SS-31 while offering mitochondrial targeting that generic CoQ10 does not.

Humanin Humanin is a mitochondria-derived peptide (a mitokine) that influences cellular survival, metabolic regulation, and neuroprotection through different mechanisms than SS-31. Where SS-31 targets membrane structure and bioenergetic efficiency, humanin operates primarily through receptor-mediated signaling cascades influencing insulin sensitivity and cell survival pathways. It represents an alternative avenue for mitochondrial health research with a distinct mechanism and a growing but still limited evidence base.

Comparison table:

Build Your SS-31 Protocol

FAQs

What is SS-31?

SS-31 (elamipretide) is a synthetic tetrapeptide (four amino acids) engineered to concentrate at the inner mitochondrial membrane, where it stabilizes cardiolipin and the protein complexes responsible for ATP production. It belongs to a class called Szeto-Schiller peptides, named for the researchers at Weill Cornell Medical College who discovered it serendipitously during opioid receptor studies in the late 1990s. It received FDA accelerated approval in September 2025 under the brand name Forzinity as the first treatment for Barth syndrome and the first mitochondria-targeted therapeutic to receive FDA approval.

What does SS-31 do?

SS-31 restores energy production in mitochondria that have been damaged by disease, aging, or ischemic injury. It does this by binding to cardiolipin, a structural lipid unique to the inner mitochondrial membrane, and stabilizing the protein complexes that generate and transport ATP. The downstream effects documented in research include improved muscle strength and exercise capacity, reduced mitochondrial-driven inflammation, protection against ischemic cell death in the heart and kidneys, and reversal of measurable aging markers in cardiac tissue.

How long does SS-31 take to work?

The timeline depends significantly on the underlying condition and the outcome being measured. In clinical trials for Barth syndrome and primary mitochondrial myopathy, meaningful improvements in muscle strength and exercise capacity were documented within the first few months of daily use, with continued improvement over 48 weeks. Acute protective effects in ischemia contexts operate within hours. Research and practitioner-tracked protocols suggest initial energy and fatigue improvements may be noticed within the first few weeks, with more substantial functional gains developing over a 2-4 month window.

What is the typical dose of SS-31?

Specific dose numbers from the pivotal human trials have not been fully disclosed in the published literature outside the FDA-approved Forzinity prescribing information for Barth syndrome. The Karaa et al. Phase 2 dose-escalation trial confirmed that higher doses produced greater increases in muscle ATP production than lower doses, establishing that SS-31 has a meaningful dose-response relationship. For the approved Forzinity indication, dosing is determined per the prescribing label under physician supervision. Investigational use in research contexts is informed by the dose-escalation designs and subcutaneous daily dosing patterns from clinical trial programs.

Is SS-31 legal?

In the United States, SS-31 is FDA-approved as Forzinity for Barth syndrome, which makes it a prescription medication for that specific indication only. Outside that approved indication, it is classified as a research compound not approved for human use. It is not currently specifically named on the WADA prohibited list, though athletes subject to anti-doping rules should verify current WADA classifications with their national anti-doping organization. Regulatory status varies by jurisdiction.

Can SS-31 be taken orally?

Oral administration is not documented as viable for SS-31. As a peptide, SS-31 is susceptible to proteolytic degradation (breakdown by digestive enzymes) in the gastrointestinal environment, and its mechanism requires direct systemic delivery for cellular uptake and mitochondrial targeting. While the D-Arginine modification provides resistance to some peptidases, the gastric acid and intestinal protease environment would be expected to degrade the compound before meaningful absorption occurs. No oral formulation or oral bioavailability data for SS-31 has been published.

What makes SS-31 different from other antioxidants?

Most antioxidants, including CoQ10, Vitamin C, and Vitamin E, work systemically or in general cellular compartments. The SS-31 peptide concentrates at the inner mitochondrial membrane at approximately 5,000-fold higher levels than the surrounding cytoplasm, targeting antioxidant activity precisely at the site where mitochondria generate most of their oxidative byproducts. Beyond direct ROS scavenging, SS-31 protects the structural membrane architecture and protein complexes that enable energy production, a mechanism no dietary antioxidant replicates. A 2024 review in the journal Mitochondrion specifically concluded that SS-31 demonstrates functional advantages over natural antioxidants in suppressing mitochondria-driven inflammation and preventing cell death.

What is the connection between SS-31 and Forzinity?

Forzinity is the FDA-approved brand name for elamipretide (SS-31) as a pharmaceutical product for Barth syndrome. The compound is the same: elamipretide is the generic drug name, and Forzinity is the commercial name under which it was approved in September 2025. Forzinity is a prescription medication available to Barth syndrome patients weighing at least 30 kg under physician supervision per its approved label. The research compound form of SS-31 available through peptide suppliers operates under a separate regulatory classification entirely.

Does SS-31 affect healthy mitochondria?

The available evidence suggests SS-31 preferentially acts on dysfunctional mitochondria rather than significantly affecting normal, healthy ones. Cellular uptake is independent of mitochondrial membrane potential, which distinguishes it from other mitochondria-targeting compounds, and its functional effects appear localized to mitochondria with damaged cardiolipin or impaired respiratory complexes. This selectivity is considered mechanistically significant for safety and is part of the basis for the favorable therapeutic window observed across clinical trials, though the exact basis of this selectivity remains under active investigation.

Why does SS-31 work longer than its half-life would suggest?

This is one of the most scientifically interesting and incompletely explained features of the SS-31 peptide. Its plasma half-life is approximately 2-4 hours, yet improvements in mitochondrial function and clinical outcomes persist for days to weeks after a dose. Proposed explanations include tissue retention beyond plasma clearance, downstream signaling cascades that continue after the drug clears, structural mitochondrial remodeling that becomes self-sustaining, and possible transcriptional changes. None has been definitively confirmed. The practical implication is that effective dosing frequency may be lower than the short half-life would otherwise suggest.

Final Thoughts on SS-31 Peptide

SS-31 occupies a genuinely unique position in the landscape of compounds discussed in the peptide and biohacking communities. It is not a tissue growth factor, a secretagogue, or a performance-adjacent research compound with forum buzz and thin preclinical data behind it. It is a mitochondria-targeted therapeutic with over two decades of rigorous clinical investigation, more than 50 published or registered trials, a landmark Phase 2/3 RCT demonstrating meaningful clinical outcomes, and FDA accelerated approval as of September 2025 as the first approved mitochondria-targeted therapeutic. That combination of scientific depth and regulatory validation is rare among compounds in this space.

What the evidence shows, in plain terms: the SS-31 peptide addresses mitochondrial dysfunction at its structural root. By stabilizing cardiolipin and the protein complexes assembled around it, it improves the efficiency of ATP production in mitochondria that have been damaged by genetic disease, aging, or ischemic injury. The effects documented in clinical trials (45% improvement in muscle strength, 40% improvement in cardiac stroke volume, reversal of cardiac aging markers in 8 weeks in an aged animal model, and improved function in failing human heart tissue) reflect genuine biological impact, not signal amplification from underpowered pilot studies. The 8-year open-label safety dataset from the Barth syndrome program provides a level of long-term tolerability data that most research compounds never accumulate.

The important caveats are real ones. The strongest evidence is in a rare genetic disease where SS-31's mechanism precisely matches the molecular defect. Whether it produces equivalent functional benefits in the broader aging and health optimization context, where mitochondrial dysfunction is present but not genetically defined, has not been tested in controlled human studies. The research compound version, outside the FDA-approved Forzinity indication, operates in an investigational context that comes with appropriate regulatory, quality, and safety considerations. For anyone working with SS-31 in that context, protocol design based on a compound this mechanistically specific and clinically novel is not something to approach generically. MyPeptidePal is built to handle exactly that: translating the compound's mechanism, the clinical data, and your individual situation into a protocol that reflects all three rather than a one-size-fits-all starting point.

References

1. Reid Thompson, W., Quigley, A. F., Bhatt, H. B., Kass, D. A., & Damian, M. S. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine, 23(3), 471-478.

2. Chatfield, K. C., Sparagna, G. C., Chau, S., Phillips, E. K., Ambardekar, A. V., Aftab, M., & Freedman, N. J. (2019). Elamipretide improves mitochondrial function in the failing human heart. JACC: Basic to Translational Science, 4(2), 147-157.

3. Chiao, Y. A., Zhang, H., Sweetwyne, M., Whitson, J., Ting, Y. S., Basisty, N., & Bhaskaran, S. (2020). Late-life restoration of mitochondrial function reverses cardiac loss of resilience in an Alzheimer's disease mouse model. eLife, 9, e55513.

4. Chavez, J. D., Tang, X., Campbell, M. D., Bhatt, H., Bhatt, D. L., Murray, K. D., & Bruce, J. E. (2020). Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences, 117(26), 15363-15373.

5. Campbell, M. D., Bhatt, H., Bhatt, D. L., Murray, K. D., Sorber, R., Bhaskaran, S., & Rabinovitch, P. S. (2019). Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine, 134, 268-281.

6. Karaa, A., Haas, R., Goldstein, A., Vockley, J., Weaver, W. D., & Cohen, B. H. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology, 90(14), e1212-e1221.

7. Stuppard, R., Marcinek, D. J., & Bhaskaran, S. (2023). Elamipretide (SS-31) treatment improves ADP uptake efficiency and respiration in aged skeletal muscle mitochondria. GeroScience, 45, 1843-1854.